You are here

MEASUREMENT OF O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE IN HUMAN TUMORS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 13737
Amount: $500,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1992
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
205 Buffalo Ave
Freeport, NY 11520
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Daniel B Yarosh
 (516) 868-9026
Business Contact
Phone: () -
Research Institution
N/A
Abstract

NITROSOUREAS ARE EFFECTIVE ANTITUMOR AGENTS, ESPECIALLY IN BRAIN CANCER. HOWEVER, TUMORS ARE OFTEN RESISTANT DUE TO ACTIVITY OF THE HUMAN DNA REPAIR ENZYME, O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE (O6MT). THE OUTCOME OF CHEMOTHERAPY MAY BE PREDICTED BY MEASURING THE LEVELS OF O6MT IN SINGLE CELLS FROM TUMOR BIOPSIES, AND A MORE RATIONAL TREATMENT REGIME MAY BE DESIGNED. THIS APPROACH IS NOW FEASIBLE BECAUSE OF THE CLONING OF THE HUMANO6MT GENE. THE PHASE I RESEARCH WILL USE POLYCLONAL ANTIBODIES AND DNA PROBES TO MEASURE O6MT LEVELS IN HUMAN TUMOR SAMPLES TAKEN AT INITIAL BIOPSY AND AT SECOND-LOOK SURGERY. THE IMMUNOHISTOCHEMICAL AND IN SITU HYBRIDIZATION ASSAY WILL BE DEVELOPED, AND TEST RESULTS WILL BE CORRELATED WITH PATIENT OUTCOME. THIS WILL ESTABLISH THE USEFULNESS OF THESE ASSAYS IN A CLINICAL TRIAL TO PREDICT DRUG RESISTANCE AND PATIENT RESPONSE TO TREATMENT.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government